Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171210 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 506
- Enrollment target
NCT00171210: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00171210 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 506 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00171210, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 506 participants
- Enrollment target
Study Summary
A 1-year randomized Phase III core trial (NCT00061750) using deferoxamine as the comparator was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older. Patients who successfully completed this main trial may continue in this extension trial to receive chelation therapy with deferasirox for an additional 4 years. The objective of this study is to assess the efficacy and long-term safety of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older.
Primary Outcome
Adverse events results are based on preferred terms with at least 7% of participants in any group.
Interventions
- DRUG Deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2004-10 |
| Phase | Phase 3 |
What the finished NCT00171210 record still lists
NCT00171210 is an interventional study that assigns participants to a tested intervention. The registered 506 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 1 intervention - of which Deferasirox is the first listed.
NCT00171210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00171210 about?
NCT00171210 is a clinical study titled "An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload". A 1-year randomized Phase III core trial (NCT00061750) using deferoxamine as the comparator was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older. Patients who successfully completed this main trial may continue in this ...
What is the current status of trial NCT00171210?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 506 participants. The study started on 2004-10.
What interventions are being tested in trial NCT00171210?
The interventions under investigation include: Deferasirox (DRUG).
Who is sponsoring clinical trial NCT00171210?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00171210's enrollment target sits among peer trials
506 741st of 2000 higher than 1,259 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05069428 · 506 participants · Phase 4
Delirium Reduction With Ramelteon
- NCT05797168 · 506 participants · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia